Recursion Pharmaceuticals Stock Slides Near Its Two-Year Low as Revenue Reverses

This Recursion Pharmaceuticals stock analysis starts with the risk profile, because the numbers demand it: shares trade at $3.49, just above the two-year low of $2.93 and far beneath the $10.53 high set earlier in that window. Market cap has fallen to $1.87 billion. The immediate trigger is a sharp reversal in revenue – trailing-twelve-month sales dropped 60.1% even though the five-year revenue CAGR is still a positive 23.3%, a gap that’s typical of a clinical-stage biotech whose revenue leans on lumpy collaboration and milestone payments rather than steady product sales. StreetBriefs’ quantitative model currently rates Recursion a Sell.

What Is Happening With the Stock Price

At $3.49, the stock sits at roughly the 7% mark of its two-year $2.93-$10.53 range – solidly at the lower end, not the middle and nowhere near the highs. That positioning reflects sustained selling pressure as the market digests both the revenue decline and the company’s continued heavy losses. There’s no dividend to cushion holders while they wait for a turnaround (dividend yield is not available, consistent with a company reinvesting – and losing – capital rather than distributing it).

Quality: Is This a Financially Sound Business?

The Quality picture is weak, and this Recursion Pharmaceuticals stock analysis won’t soften it: net profit margin is 0.0% and gross margin is also reported at 0.0%, an unusual pairing that likely reflects how collaboration-revenue accounting nets against cost of revenue for a company with minimal product sales – not a sign the underlying science is worthless, but a sign there is essentially no profitable core business yet. Return on assets is -27.3% and return on equity is -56.6%. Operating margin of -1759.7% looks extreme, and it is – on just $55 million of trailing revenue, operating expenses (R&D-heavy, as is standard for clinical-stage biotech) run many multiples of sales, so the ratio balloons even though the dollar loss is a more modest scale relative to the company’s $1.87 billion market cap. Free cash flow is negative $219 million (FCF yield -11.7%), a real and ongoing cash burn. The offsetting positive: leverage is minimal, with debt-to-equity of just 0.07, and liquidity is strong, with a current ratio of 5.03 and quick ratio of 4.67 – the balance sheet can absorb losses for a while, even if it can’t do so forever.

Growth: Does This Company Have Real Upside?

Growth is where the story gets genuinely mixed. The trailing-twelve-month revenue decline of 60.1% is the number driving today’s Sell signal, but the five-year revenue CAGR of 23.3% shows that on a longer horizon, top line has still grown – just not smoothly, and not in the most recent year. Earnings growth for the TTM period is not available, since the company remains unprofitable on that basis. EV/Revenue of 26.01 is a valuation multiple more typical of a business assumed to be scaling fast, which sits uneasily next to a revenue base that just contracted sharply – a tension investors should weigh rather than ignore.

Opportunity: Is Now a Good Time to Enter?

With no P/E ratio available (the company has negative earnings), valuation has to lean on other yardsticks. Price-to-book of 2.04 is not extreme, but EV/Revenue of 26.01 is rich for a company with declining trailing revenue, and EV/EBITDA is negative at -3.02, reflecting negative earnings before interest, tax, depreciation and amortization. The stock’s position near the bottom of its two-year range could appeal to contrarian, high-risk-tolerance investors betting on a pipeline turnaround, but the current multiples don’t look cheap against the fundamentals as they stand today – they still look priced for a turnaround story that hasn’t been delivered yet.

Recursion Pharmaceuticals Stock Analysis: The Bottom Line

Pulling the three pillars together, this Recursion Pharmaceuticals stock analysis lands on a clear risk warning rather than a buying opportunity: Quality scores just 25/100 on continued losses and cash burn, Growth scores 15/100 on the recent revenue reversal despite a decent longer-run trend, and Opportunity scores 25/100 as valuation multiples remain elevated relative to shrinking trailing revenue. Together those produce a Recommendation Score of 22/100 and StreetBriefs’ model signal of Sell. The clearest risk is straightforward: continued cash burn against a shrinking revenue base could force further dilution or a slower path to profitability than the stock’s multiple implies, even though minimal debt and strong liquidity buy the company time. As always, Buy/Hold/Sell reflects StreetBriefs’ quantitative scoring model based on Quality, Growth, and Opportunity – a data-driven research signal, not a personalized recommendation to transact.